Author

Christopher A. Bravery

Observed names: C A Bravery, C A. Bravery, C A.B. Bravery, C Bravery, C. A. Bravery, C. Bravery, C.A. Bravery, CHRISTOPHER A. BRAVERY, Christopher A Bravery, Christopher Bravery

Observed institutions: University of London, Guy's Hospital, St Thomas' Hospital, The Royal Free Hospital, Biomedical Primate Research Centre, Harefield Hospital, Novartis (United Kingdom), International Society for Cellular Therapy, King's College Hospital, Intercytex (United Kingdom), University College London

OpenAlex ID: A5018660245

Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry

2013 · Christopher A. Bravery, Jessica Carmen, et al. · Cytotherapy · 195

Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women

1999 · Yufei Wang, Louisa Tao, et al. · Nature Medicine · 103

Direct Recognition of Sla- and Hla-like Class Ii Antigens on Porcine Endothelium by Human T Cells Results in T Cell Activation and Release of Interleukin-2

1995 · CHRISTOPHER A. BRAVERY, PUSPA BATTEN, et al. · Transplantation · 92

Generation of CD8 suppressor factor and β chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques

1998 · Yufei Wang, Louisa Tao, et al. · Proceedings of the National Academy of Sciences · 65

Do Human Leukocyte Antigen-Typed Cellular Therapeutics Based on Induced Pluripotent Stem Cells Make Commercial Sense?

2014 · Christopher A. Bravery · Stem Cells and Development · 60

Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals

2020 · Magdi Elsallab, Christopher A. Bravery, et al. · Molecular Therapy — Methods & Clinical Development · 59

PDF

The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders' concerns

2014 · Natividad Cuende, Christelle Boniface, et al. · Cytotherapy · 51

Increasing renal mass improves survival in anephric rats following metanephros transplantation

2006 · Damian Marshall, Mark R. Dilworth, et al. · Experimental Physiology · 50

Up‐regulation of β‐chemokines and down‐modulation of CCR5 co‐receptors inhibit simian immunodeficiency virus transmission in non‐human primates

2000 · T. Lehner, Y. Wang, et al. · Immunology · 42

PDF

Enabling Consistency in Pluripotent Stem Cell-Derived Products for Research and Development and Clinical Applications Through Material Standards

2015 · Anna French, Christopher Bravery, et al. · Stem Cells Translational Medicine · 36

PDF

Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism

1999 · Kamuran Mengubas, Fiona A Riordan, et al. · Oncogene · 36

Herbimycin A accelerates the induction of apoptosis following etoposide treatment or γ-irradiation of bcr/abl-positive leukaemia cells

1998 · Fiona A Riordan, Christopher A Bravery, et al. · Oncogene · 29

Identification, detection, and in vitro characterization of cynomolgus monkey natural killer cells in delayed xenograft rejection of hDAF transgenic porcine renal xenografts

2000 · D Quan, C Bravery, et al. · Transplantation Proceedings · 28

Transplantation of metanephroi to sites within the abdominal cavity

2005 · D. Marshall, M. Clancy, et al. · Transplantation Proceedings · 25

Development and functional capacity of transplanted rat metanephroi

2007 · M. R. Dilworth, M. J. Clancy, et al. · Nephrology Dialysis Transplantation · 24

Human Cd154 Induces Activation of Porcine Endothelial Cells and Up-regulation of Mhc Class Ii Expression

2001 · Stuart A. Rushworth, Christopher A. Bravery, et al. · Transplantation · 20

EU market authorisation strategy: lessons from the first 22 ATMP submitted to the EMA

2019 · Christopher A Bravery, Oliver Ball, et al. · Cell and Gene Therapy Insights · 14

Reference materials for cellular therapeutics

2014 · Christopher A. Bravery, Anna French · Cytotherapy · 11

Expression of ABH antigens in porcine heart tissue.

1992 · C A Bravery, B J Hunt, et al. · PubMed · 11

High Sequence Homology Between Human and Pig Cd40 With Conserved Binding to Human Cd154

2000 · Stuart A. Rushworth, Christopher A. Bravery, et al. · Transplantation · 10

Bioprocessing considerations for generation of iPSCs intended for clinical application: perspectives from the ISCT Emerging Regenerative Medicine Technology working group

2024 · Hannah W. Song, Jennifer N. Solomon, et al. · Cytotherapy · 9

PDF

Regulating interface science healthcare products: myths and uncertainties

2010 · Christopher A. Bravery · Journal of The Royal Society Interface · 9

Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products

2015 · Takao Hayakawa, Takashi Aoi, et al. · Biologicals · 8

Preservation of embryonic kidneys for transplantation

2005 · M.J. Bottomley, S. Baicu, et al. · Transplantation Proceedings · 8

Translation and commercialization of regenerative medicines

2010 · Julia Polak, Christopher A. Bravery, et al. · Journal of The Royal Society Interface · 7

Works count: 43

Citation count: 1,023

H-index: 16

I10-index: 20